Open-label, Non-randomized, Phase 2 Study Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Trial Profile

Open-label, Non-randomized, Phase 2 Study Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs PQR 309 (Primary)
  • Indications Lymphoma
  • Focus Therapeutic Use
  • Sponsors PIQUR Therapeutics
  • Most Recent Events

    • 19 Apr 2017 Last checked against ClinicalTrials.gov record.
    • 13 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Apr 2018.
    • 13 Apr 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top